Vertaling van "eds " (Nederlands → Frans) :

TERMINOLOGIE

EDS VIA - Ehlers-Danlos-syndroom type 6A
syndrome d'Ehlers-Danlos type cyphoscoliotique

IN-CONTEXT TRANSLATIONS

[V - Wet 22-8-02 - B.S. 10-9; W – Wet(I) 24-12-02 - B.S. 31-12 - ed.1; W – Wet(I) 22-12-03 - B.S. 31-12 - ed.1; W - Wet 9-7-04 - B.S. 15-7 - ed.2; W - Wet 25-11-04 - B.S. 7-12 - ed.2; W – Wet(Prog) 27-12-04 - B.S. 31-12 - ed.2; W - K.B. 27-4-05 - B.S. 20-5 – ed. 2; W – Wet 19-12-08 – B.S. 31-12 – ed. 3 – art. 48]
[R - Loi 22-8-02 - M.B. 10-9; M – Loi(I) 24-12-02 - M.B. 31-12 - éd.1; M – Loi(I) 22- 12-03 - M.B. 31-12 - éd. 1; M - Loi 9-7-04 - M.B. 15-7 - éd. 2; M - Loi 25-11-04 - M.B. 7-12 - éd. 2; M – Loi(Prog.) 27-12-04 - M.B. 31-12 - éd. 2; M - A.R. 27-4-05 - M.B. 20-5 - éd. 2; M - Loi 19- 12-08 - M.B. 31-12 - éd. 3 - art. 48]

[V - Wet 10-8-01 - B.S. 1-9 - ed.2; W – Wet(I) 24-12-02 - B.S. 31-12 - ed.1; W – Wet(I) 22- 12-03 - B.S. 31-12 - ed.1; W – Wet(Prog) 27-12-04 - B.S. 31-12-04 - ed.2; W – Wet(Prog) 27-12- 05 - B.S. 30-12 - ed. 2]
(°) d'application à partir du 30-12-2009 (A.R. 17-12-09 – M.B. 30-12 - art. 1) (°°) d'application à partir du 30-12-2009 (A.R. 17-12-09 – M.B. 30-12 - art. 1)

[I - Wet 22-12-03 - B.S. 31-12 - ed.1; W - Wet 9-7-04 - B.S. 15-7 - ed.2; W – Wet(Prog) 27- 12-04 - B.S. 31-12 - ed.2; W – Wet 19-12-08 – B.S. 31-12 - ed. 3 – art. 48]
[I - Loi 22-12-03 - M.B. 31-12 - éd. 1; M - Loi 9-7-04 - M.B. 15-7 - éd. 2; M – Loi(Prog.) 27-12-04 - M.B. 31-12 - éd. 2 ; M - Loi 19-12-08 - M.B. 31-12 - éd. 3 - art. 48]

[V – Wet(I) 22-12-03 - B.S. 31-12 - ed.1; W – Wet 19-12-08 – B.S. 31-12 – ed. 3 – art. 52; W – Wet(prog)(I) 17-6-09 - B.S. 26-6 - ed. 2 - art. 16; W – Wet(prog) 27-12-12 - B.S. 31-12 – ed 2
[R - Loi (I) 22-12-03 - M.B. 31-12 - éd. 1; M - Loi 19-12-08 - M.B. 31-12 - éd. 3 - art. 52; M - Loi (prog) (I) 17-6-09 - M.B. 26-6 - éd. 2 - art. 16; M – Loi (prog) 27-12-12 – M.B. 31-12 – éd. 2 – art. 10]

[W – Wet(Prog) 27-12-04 - B.S. 31-12 - ed.2; W – Wet(Prog) 27-12-05 - B.S. 30-12 - ed.2; W - Wet(div) 10-12-09 - B.S. 31-12 - ed. 3 - art. 51]
[M – Loi (prog) 27-12-04 – M.B. 31-12 – éd. 2; ; M – Loi (prog) 27-12-05 - M.B. 30-12 - éd. 2 ; M - Loi (div) 10-12-09 - M.B. 31-12 - éd. 3 - art. 51]

[W – Wet(Prog) 27-12-05 - B.S. 30-12 - ed.2; W – Wet (div) (I) 24-7-08 - B.S. 7-8 - art. 96; W - Wet(prog)(1) 23-12-09 - B.S. 30-12 - ed. 1 - art. 46; W – Wet(prog)(1) 22-6-12 - B.S. 28-6 - art. 127; W – Wet(prog)(1) 28-6-13 - B.S. 1-7 - ed. 2 - art. 27]
[M – Loi (prog) 27-12-05 - M.B. 30-12 - éd. 2; M – Loi (div) (I) 24-7-08 – M.B. 7-8 – art. 96; M – Loi (prog) (I) 23-12-09 - M.B. 30-12 - éd. 1 - art. 46; M – Loi (prog) (I) 22-6-12 – M.B. 28-6 – art. 127; M – Loi (prog) (1) 28-6-13 – M.B. 1-7 – éd. 2 – art. 27]

§ 1. [W – Wet(Prog) 27-12-04 - B.S. 31-12-04 - ed.2; W – Wet(Prog) 27-12- 05 - B.S. 30-12 - ed.2; W - Wet 13-12-06 - B.S. 22-12 - ed. 2]
§ 1er. [M – Loi(Prog) 27-12-04 - M.B. 31-12 - éd. 2; M – Loi(Prog) 27-12-05 - M.B. 30-12 - éd. 2; M - Loi 13-12-06 - M.B. 22-12 - éd. 2]

●● Efficacy: the active ingredient is as such subject to an authorisation or prequalification by the WHO or a positive opinion from the EMEA During this first year of activity, The Production & Distribution department issued 149 EDs.
●● Efficacy: the active ingredient is as such subject to an authorisation or prequalification by the WHO or a positive opinion from the EMEA During this first year of activity, The Production & Distribution department issued 149 EDs.

However, such medicines do have to meet a number of quality and efficacy conditions, which are investigated in connection with the ED.
However, such medicines do have to meet a number of quality and efficacy conditions, which are investigated in connection with the ED.

Exportdeclaraties Geneesmiddelen met een “exportdeclaratie” (ED) zijn geneesmiddelen die exclusief bestemd zijn
Déclarations d’exportation Les médicaments avec une «déclaration d’exportation» (ED) sont des médicaments exclusivement destinés à des marchés non européens et donc non soumis à un processus d’autorisation de mise